INFORMATION:
Additional information:
VTT
Dr. Marko Kallio, Principal Scientist
Tel. +358 20 722 2810
marko.kallio@vtt.fi
Further information on VTT:
Olli Ernvall
Senior Vice President, Communications
358 20 722 6747
olli.ernvall@vtt.fi
http://www.vtt.fi
VTT Technical Research Centre of Finland
VTT is a leading multitechnological applied research organization in Northern Europe. VTT creates new technology and science-based innovations in co-operation with domestic and foreign partners. Every third Finnish technology innovation contains VTT expertise. VTT's turnover is EUR 310 million and its personnel totals 2,900.
Earlier unknown molecular-level mechanism may increase the growth of breast cancer cells
2014-10-20
(Press-News.org) Researchers at VTT Technical Research Centre of Finland, the University of Turku and the University of Oslo have discovered a previously unknown molecular-level mechanism that may partly explain the increased growth of cancer cells. The study, published in the British Journal of Cancer, showed that high levels of miRNA-378a-5p molecule cause cell division anomalies. This renders the number of chromosomes in cancer cells abnormal, which is known to promote growth and the spread of cancer. In addition, the researchers discovered that elevated miRNA378a-5p levels in breast cancer patients correlate with the most aggressive forms of cancer. The objective is to develop new diagnostic methods for breast cancer on the basis of the research results
MicroRNAs are small intracellular RNA molecules that regulate gene expression. Therefore, they play important roles in various normal processes of the human body, such as embryogenesis, and the regulation of cell viability. In addition, it is known that abnormal amounts of microRNA stimulate the onset and development of different diseases, such as cancer.
The objective of the research project lead by Marko Kallio, Principal Scientist at VTT, was to identify novel microRNAs participating in the regulation of cell division among the over 1000 microRNAs found in human. In the study it was found that elevated miR-378a-5p levels perturb mitotic fidelity, which is known to be one of the factors promoting the generation, growth and spread of cancer.
The researchers also succeeded in discovering a molecule-level mechanism that can explain the observed chromosome changes caused by over-expression of miR-378a-5p; excess of this particular microRNA in cancer cells leads to significant suppression of Aurora B kinase, which is an essential protein needed for faithful cell division. In addition, over-expression of miR-378a-5p was found to reduce the sensitivity of cancer cells to paclitaxel treatment and to activate certain cell surface receptors, which transmit signals regulating, for example, angiogenesis. The observation concerning activation of receptors is consistent with a Canadian study published earlier showing that over-expression of miR-378a-5p stimulates neovascularization in tumours.
In addition to the new observations concerning pathogenesis of cancer and drug response of cancer cells, the Finnish-Norwegian study is also significant due to the research results obtained from the tumours of breast cancer patients. Elevated miR-378a-5p levels were detected particularly in the most aggressive grade 3 breast tumours, which have poor patient outlook. In the future, the research group will attempt to verify the results in a more extensive patient study, with the additional objective of developing new diagnostic methods based on the expression of microRNA molecules.
The results of the research project headed by Dr. Kallio give new perspectives on earlier microRNA studies, and reinforce the theory that cancer cells take advantage of microRNA molecules when striving to multiply and spread. In case of the miR-378a-5p, its over-expression in cancer tissue may stimulate angiogenesis in tumours, enhance the energy metabolism of cancer cells, reduce the sensitivity of cancer cells to paclitaxel therapy, and induce chromosome changes, that all help cancer gain growth advantage.
ELSE PRESS RELEASES FROM THIS DATE:
Physicists build reversible laser tractor beam
2014-10-20
Laser physicists have built a tractor beam that can repel and attract objects, using a hollow laser beam that is bright around the edges and dark in its centre.
It is the first long-distance optical tractor beam and moved particles one fifth of a millimetre in diameter a distance of up to 20 centimetres, around 100 times further than previous experiments.
"Demonstration of a large scale laser beam like this is a kind of holy grail for laser physicists," said Professor Wieslaw Krolikowski, from the Research School of Physics and Engineering at The Australian National ...
1980s American aircraft helps quantum technology take flight
2014-10-20
What does a 1980s experimental aircraft have to do with state-of-the art quantum technology? Lots, as shown by new research from the Quantum Control Laboratory at the University of Sydney, and published in Nature Physics today.
Over several years a team of scientists has taken inspiration from aerospace research and development programs to make unusually shaped experimental aircraft fly.
"It always amazed me that the X-29, an American airplane that was designed like a dart being thrown backwards, was able to fly. Achieving this, in 1984, came through major advances ...
New class of drugs shows promise in treating chronic diarrhea
2014-10-20
A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.
Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea that is estimated to affect one in 100 adults in western countries, but is often mistaken for irritable bowel syndrome (IBS) by doctors. Many patients are not diagnosed correctly and undergo repeated unnecessary tests.
The study at Imperial College London found that the drug obeticholic acid (OCA) could provide relief for patients with BAD. OCA is the first in a new class ...
New study demonstrates advances in creating treatment for common childhood blood cancer
2014-10-20
Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia.
Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme "switch" needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia.
An estimated quarter of the 500 U.S. adolescents and young adults diagnosed each year with this aggressive disease fail to respond to standard chemotherapy drugs that target cancer ...
Wild molecular interactions in a new hydrogen mixture
2014-10-20
Washington, D.C.— Hydrogen—the most abundant element in the cosmos—responds to extremes of pressure and temperature differently. Under ambient conditions hydrogen is a gaseous two-atom molecule. As confinement pressure increases, the molecules adopt different states of matter—like when water ice melts to liquid and then heats to steam. Thus far, at extreme pressures hydrogen has four known solid phases. Now scientists, including Carnegie's Alexander Goncharov, have combined hydrogen with its heavier sibling deuterium—which has an added neutron ...
Specialty drugs -- Cost, impact & value: Health Affairs' October issue
2014-10-20
This issue of Health Affairs was supported by CVS Health.
Do specialty drugs offer value that offsets their high costs?
James D. Chambers of Tufts Medical Center and coauthors conducted a cost-value review of specialty versus traditional drugs by analyzing incremental health gains associated with each. This first-of-its-kind analysis is timely because the majority of drugs now approved by the Food and Drug Administration are specialty drugs produced using advanced biotechnology and requiring special administration, monitoring, and handling—all of which result ...
HCV treatment breakthroughs highlighted at ACG 2014
2014-10-20
Philadelphia, PA (October 20, 2014)–Promising new research in the area of hepatitis C (HCV) therapy that suggests more patients, including those with cirrhosis, will be cured from this common cause of potentially fatal viral liver disease; as well as a number of abstracts that advance understanding of the safety and effectiveness of fecal microbiota transplantation for Clostridium difficile, are among the highlights of the American College of Gastroenterology's (ACG) 79th Annual Scientific Meeting , which will be held this week in Philadelphia. More than 4,000 ...
New tracers can identify frack fluids in the environment
2014-10-20
DURHAM, N.C. – Scientists have developed new geochemical tracers that can identify hydraulic fracturing flowback fluids that have been spilled or released into the environment.
The tracers, which were created by a team of U.S. and French researchers, have been field-tested at a spill site in West Virginia and downstream from an oil and gas brine wastewater treatment plant in Pennsylvania.
"This gives us new forensic tools to detect if 'frac fluids' are escaping into our water supply and what risks, if any, they might pose," said Duke University geochemist Avner ...
iPads detect early signs of glaucoma in Nepal eye screening
2014-10-20
CHICAGO – Oct. 20, 2014 – Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. In this study, researchers from the University of Iowa, the University of Maryland, Johns Hopkins University, the University of Michigan and the Tilganga Eye Institute in Nepal used a free peripheral vision assessment ...
3-D printed facial prosthesis offers new hope for eye cancer patients following surgery
2014-10-20
CHICAGO – Oct. 20, 2014 – Researchers have developed a fast and inexpensive way to make facial prostheses for eye cancer patients using facial scanning software and 3-D printing, according to findings released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. Their novel process can create more affordable prosthetics for any patients who have hollow sockets resulting from eye surgery following cancer or congenital deformities.
In the United States, more than 2,700 new cases of eye cancer are diagnosed each year, according ...